DDInter1863 DDInter1376
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Triclabendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triclabendazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Triclabendazole may lead to a major life threatening interaction when taken with Ivosidenib